SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is a top trending stock following its recent earnings report, which showed stronger-than-expected results for the past quarter but included a weaker outlook for the current period due to supply constraints and manufacturing yields. This mixed news has sparked a fervent debate among investors, with many long-term bulls seeing a buying opportunity in the face of temporary challenges, citing the company's AI initiatives, advanced 18A node, and government backing for its foundry efforts. However, others remain cautious, pointing to the soft guidance as evidence of ongoing competitive struggles and concerns about the stock's valuation after its recent strong rally.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune ($ALT) is surging with strong buying interest, as the stock has rallied past key technical resistance levels and achieved a notable close. This momentum is largely driven by investor anticipation following its FDA Breakthrough Therapy Designation for Pemvidutide, fueling widespread speculation of an imminent partnership or acquisition in the active GLP-1/MASH sector. The community is also keenly watching for a potential short squeeze and increased institutional investment now that the stock is trading above $5.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as CEO Ryan Cohen has significantly increased his stake, publicly challenging other CEOs to demonstrate similar conviction by buying shares with their own money. This substantial insider activity has ignited widespread community excitement, driving speculation about a potential short squeeze and rallying cries like "shorts are f****d." The renewed focus on insider alignment and the re-emergence of the meme stock narrative are fueling intense discussion.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as it formally submitted the first consolidated deep-sea mining application under NOAA's new expedited permitting framework, significantly expanding its proposed commercial recovery area. The community is actively discussing how this, combined with a crucial Congressional hearing on seabed metals for national security, substantially derisks the project and signals potential government backing for critical mineral independence.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is experiencing a surge in attention due to its extremely low share float and high short interest, fueling intense community speculation for a significant short squeeze. Traders are actively comparing it to other recent microcap parabolic runners, anticipating substantial price increases as the company explores strategic alternatives.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently announced $150 million direct offering of common shares, sparking widespread discussion. While some investors express concern over dilution and a perceived lack of immediate commercialization news, many see this capital raise as a strategic, bullish move. The community anticipates the funds will accelerate production capabilities and facilitate potential acquisitions like Sivers Semiconductors, positioning POET to meet future demand for its optical interposer technology in the rapidly growing AI data center market, further bolstered by a recent product innovation award.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending amid persistent acquisition rumors, notably involving Datadog and Google, even as the stock recently plunged post-earnings despite beating estimates due to conservative guidance and sector-wide growth concerns. The community is polarized, with many anticipating a significant buyout premium, while others point to market manipulation and a 'show me' mentality from investors looking for stronger GAAP profitability in the current software environment.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as gold surges to new all-time highs, boosted by an upgraded price target from Goldman Sachs and widespread discussions about its role as a safe haven. While many investors celebrate short squeezes and gold's resilience amidst global uncertainties, a significant segment of the community warns of a speculative 'mania' and anticipates a sharp pullback.

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

60 Degrees Pharmaceuticals Inc

SXTP is trending following news of its partnership with Runway Health, aiming to broaden telehealth access for its malaria prevention drug, ARAKODA, which has ignited a significant price surge. The community is sharply divided, with bulls celebrating substantial gains and anticipating further upside due to the low float, while skeptics caution about a potential 'pump and dump' and impending dilution.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is drawing significant attention as Elon Musk's comments on solar-powered AI satellites and data centers in space highlight the demand for advanced space infrastructure. The market is actively discussing ASTI's lightweight, flexible thin-film solar technology, seeing it as critical for next-gen constellations and defense initiatives, alongside its strategic partnerships. This has fueled community speculation about a potential short squeeze and substantial upside, given the company's low market capitalization in a rapidly expanding sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin Mcculloch sold 15,000 shares of the business's stock in a transaction on Thursday, January 8th. The shares were sold at an...

Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - Here's Why

Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - What's Next...

John Patrick Shannon, Jr. Sells 24,907 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 24,907 shares of Xeris Biopharma stock in a transaction that occurred on Monday, January 5th. The...

Xeris Biopharma (NASDAQ:XERS) Insider Sells $176,341.56 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 24,907 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The...

Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of...

Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the business's stock in a transaction on Friday, January 2nd. The stock was sold at an average...

Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Diversified Trust Co

Diversified Trust Co trimmed its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 81.2% in the third quarter, according to its most recent filing with the...

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Xeris Biopharma (NASDAQ:XERS) Trading Down 6.8% - Time to Sell?

Xeris Biopharma (NASDAQ:XERS) Trading Down 6.8% - Here's Why...

Calamos Advisors LLC Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS

Calamos Advisors LLC bought a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

What&#39;s the biggest driver of market volatility right now?

Stocktwits

What's the biggest driver of market volatility right now?

Current Price	$7.61
Prev Close	$7.62
Open	$7.70
Dividend Yield	0.00%
50-Day Moving Average	$7.24
Beta	1.32
Avg. Volume	2.2M
PE Ratio	-73.69

52-Week High	$10.08
52-Week Low	$3.24
Market Capitalization	$1.26B
EPS (Annual)	-$0.3736
Price to Book	-1,465.38
Revenue Per Employee	$515,406.09
Enterprise Value/EBITDA	N/A

XERS
Xeris Biopharma Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XERS News

XERSXeris Biopharma Holdings Inc